Table 4.37Cost-effectiveness results for non-dominated strategies taking into account price discounts for generic pharmaceutical products

StrategyCostIncremental costEffectiveness (QALYs)Incremental effectiveness (QALYs)ICER
FOLFOX-irinotecan£ 11,136-0.925--
FOLFOX-FOLFIRI£ 12,029£ 8930.9440.019 QALY£47,801/QALY

From: 4, Management of Metastatic Disease

Cover of Colorectal Cancer
Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer.
NICE Clinical Guidelines, No. 131.
National Collaborating Centre for Cancer (UK).
Copyright © 2011, National Collaborating Centre for Cancer.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.